Proficio Capital Partners’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$597K Sell
3,102
-1,149
-27% -$124K 0.02% 199
2026
Q2
$298K Buy
+4,251
New +$220K 0.01% 502
2024
Q4
– Sell
-3,261
Closed -$218K – 373
2024
Q3
$218K Sell
3,261
-667
-17% -$61.2K 0.02% 264
2024
Q2
$466K Buy
3,928
+158
+4% +$20K 0.05% 173
2024
Q1
$402K Buy
3,770
+376
+11% +$37.9K 0.04% 197
2023
Q4
$338K Sell
3,394
-3
-0.1% -$252 0.04% 200
2023
Q3
$351K Buy
+3,397
New +$379K 0.05% 190
2022
Q1
– Sell
-979
Closed -$249K – 317
2021
Q4
$249K Sell
979
-13
-1% -$3.8K 0.03% 253
2021
Q3
$382K Sell
992
-105
-10% -$38.7K 0.05% 176
2021
Q2
$258K Buy
+1,097
New +$196K 0.03% 237
2019
Q3
– Sell
-67
Closed -$1K – 994
2019
Q2
$1K Buy
+67
New +$1.44K ﹤0.01% 1762

Other funds holding MRNA

Proficio Capital Partners's MRNA Position: Q3 2026 in Review

Proficio Capital Partners reduced its Moderna (MRNA) stake by 27% in Q3 2026, selling an estimated $124K and leaving 3,102 shares worth $597K. The position accounts for 0.02% of the portfolio, ranked #199.

Proficio Capital Partners first reported a position in MRNA in Q2 2019 and has held it in 11 quarters since. 1,053 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Proficio Capital Partners held 3,102 shares of Moderna worth $597K as of Q3 2026.
  • Proficio Capital Partners sold 1,149 Moderna shares in Q3 2026, an estimated $124K.
  • Moderna made up 0.02% of Proficio Capital Partners's portfolio in Q3 2026, its #199 holding.
  • Proficio Capital Partners first reported a position in Moderna in Q2 2019 and has held it in 11 quarters since.
  • 1,053 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Proficio Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.